Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691938 · ClinicalTrials.gov registry record · Phase 1
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00691938 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 52 participants.
The verdict
NCT00691938, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥ 60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia.
Interventions
- DRUG Decitabine
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-06 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691938
The ClinicalTrials.gov registry entry for NCT00691938 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT00691938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00691938 about?
NCT00691938 is a clinical study titled "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)". This study is designed to evaluate the combination of LBH589 and decitabine in patients age ≥ 60 years with high risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia.
What is the current status of trial NCT00691938?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-06. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00691938?
The interventions under investigation include: Decitabine (DRUG), LBH589 (DRUG).
Who is sponsoring clinical trial NCT00691938?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.